Tinostamustine

The research will assess potential next-generation disease-modifying treatment for Alzheimer’s disease. Credit: Dragana Gordic via Shutterstock. Swedish research-based biopharma company BioArctic has signed an agreement with Eisai for a research evaluation focusing on BAN2802, a novel Alzheimer’s disease (AD) treatment candidate. The BAN2802 treatment combines BioArctic’s BrainTransporter technology with an undisclosed Alzheimer’s drug candidate. The BrainTransporter technology is intended to actively transport antibodies across the blood-brain barrier to enhance the treatment efficacy. Eisai, at the end of the collaboration, will assess the data generated. It can then decide to exercise an option to license BAN2802 for the treatment of Alzheimer’s disease. BioArctic and Eisai’s partnership dates back to 2005, for the development and commercialisation of drugs for Alzheimer’s disease treatment. See Also: BioMarin Pharmaceutical gets grant for treatment of adolescent PKU patients using AVPAL variant Purdue Pharma gets grant for treatment of T-cell prolymphocytic leukemia using tinostamustine Their collaboration has already resulted in the development of Leqembi (lecanemab), a drug that slows the progression of early Alzheimer’s disease. The new partnership aims to further this success in the field of Alzheimer’s disease. BioArctic CEO Gunilla Osswald said: “I am very happy that our Brain Transporter technology has continued to progress so well and that we have now entered into this first agreement utilising this platform. I believe that this technology has huge potential to improve many different projects, and support companies in their pursuit of helping people with brain disorders. “Together, we have been able to deliver lecanemab, the first fully approved disease-modifying treatment in Alzheimer’s disease in the US, Japan and China, and we look forward to continuing our fruitful collaboration and lead the development of the next generation of drugs to help patients with this devastating disease.” The research evaluation programme will be a joint financial effort. It will assess potential next-generation disease-modifying treatments for AD. BioArctic said its BrainTransporter technology facilitates the active transport of biologics across the blood-brain barrier into the brain, potentially leading to more rapid and potent treatment outcomes. Earlier this year, BioArctic and Eisai obtained approval for the amyloid beta-directed antibody Leqembi in China to treat mild cognitive impairment associated with Alzheimer’s disease and mild AD dementia.